Multiple sclerosis (MS) is considered to be an autoimmune demyelinating disorder, but recent studies showed that axonal degeneration is also an important pathological feature of MS. Indeed, Nogo receptor-1 and its ligands have been identified as key molecules for axonal degeneration in various neurological disorders, including MS. Lateral olfactory tract usher substance, an endogenous Nogo receptor-1 antagonist, promotes axonal growth and regeneration by blocking Nogo receptor-1 signaling. We found that the lateral olfactory tract usher substance level in cerebrospinal fluid was inversely correlated with MS disease activity. Here, we review the association between the key molecules in axonal degeneration/regeneration and MS, and discuss the potential application of lateral olfactory tract usher substance as a biomarker and therapeutic target of MS.
Introduction
For decades, multiple sclerosis (MS) has been considered to be an inflammatory demyelinating disease of the central nervous system (CNS). However, recent studies showed that axonal degeneration is a pathological feature and important pathogenic mechanism in MS. Axonal degeneration is generally recognized to begin in the late or progressive stage of MS, 1,2 but recent pathological and magnetic resonance imaging (MRI) studies have shown that widespread and prominent axonal degeneration can be observed even in the early clinical stages. 3 Continuous and progressive axonal degeneration is now considered one of the important causative mechanisms leading to irreversible neurological disability in the late clinical stages of MS. 4, 5 Despite the contribution of axonal degeneration to MS pathogenesis in early-to-late clinical stages, its mechanism has yet to be fully elucidated.
Recent studies have shown that several molecules involved the inhibition of axonal regeneration are critical for axonal degeneration in MS. In particular, myelin-associated inhibitors (MAI) and their common receptor, Nogo receptor-1 (NgR1), have attracted attention as the key molecules directly related to axonal degeneration; accordingly, they are considered promising targets for novel MS therapeutics. 6, 7 In addition to these molecules, we recently identified the novel molecule, lateral olfactory tract usher substance (LOTUS), an endogenous antagonist against NgR1, which strongly prevents MAI signal transduction through their receptor, and promotes axonal growth and neuronal regeneration. 8, 9 In addition to MAI, chondroitin sulfate proteoglycans (CSPG) have recently been identified as important functional ligands for NgR1, which are upregulated in the glial scar and inhibits axon regeneration after CNS injury. Importantly, we showed in a recent study that LOTUS suppressed CSPG-induced axonal growth inhibition, as well as MAI-induced inhibition, suggesting that LOTUS represents a promising therapeutic target for promotion of axon regeneration. 10 Furthermore, we detected LOTUS in human cerebrospinal fluid (CSF) and showed that its concentration is inversely correlated with the disease activity of MS.
In the following sections, we review the association between MS and the key molecules involved in axonal degeneration/regeneration, and discuss the application of LOTUS as a biomarker for MS from a clinical perspective.
Molecules related to axonal degeneration
Regeneration of adult mammalian CNS tissues after brain or spinal injury is challenging, because neurons do not easily regenerate. In addition, the environment around injured sites of the CNS strongly suppresses neuronal regeneration, and CNS myelin is among the most important environmental factors. The components of myelin include Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein, all of which are MAIs that exert an inhibitory effect on neuronal regeneration. [11] [12] [13] [14] [15] [16] [17] In addition, glial scars that form following CNS damage represent another environmental factor that restricts neuronal regeneration, and CSPG play a key role in this phenomenon. 18 Despite their lack of sequence homology, NgR1 serves as a common receptor for these molecules. On ligand binding, NgR1 activates downstream signaling molecules including Ras homolog family member A and Ras homolog-associated kinase, resulting in axonal degeneration. 19 Based on these mechanisms, several different types of therapeutic strategies targeting Nogo and/or NgR1-mediated signaling have been adopted in animal models, and several reports have shown that suppression of this signaling pathway promotes neuronal regeneration and functional recovery. [20] [21] [22] [23] The most promising strategy involves molecules targeting NgR1, such as NEP1-40, a partial inhibitor of Nogo-binding to NgR1, 24 and a decoy receptor made from the ectodomain of NgR1, 25, 26 suggesting the importance of antagonizing NgR1.
Recently, we identified LOTUS as a key molecule for formation of the lateral olfactory tract and showed that it also acts as an endogenous NgR1 antagonist by preventing binding of Nogo, the representative MAI. 8 Furthermore, we showed that LOTUS prevented NgR1 binding by almost all ligands including other MAI, such as myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, B lymphocyte stimulator and newly identified CSPG. 9, 10, 27 These findings imply that LOTUS plays key roles in promoting axonal regeneration by strongly antagonizing NgR1 (Fig. 1) , and therefore represents a promising therapeutic target for axonal degeneration in various neurological disorders.
NgR1 is a key molecule in axonal degeneration in MS
MS shows various clinical symptoms caused by inflammation and demyelination in the CNS, and is classified into three subtypes according to its clinical course. The conventional type of MS is characterized by repeated relapses and remissions in the early clinical stages, and is referred to as relapsing-remitting MS (RRMS). Some patients with RRMS show slowly progressive dysfunction with few or no apparent relapses in the late clinical stages (secondary progressive MS: SPMS). The third type of MS is primary progressive MS, which is characterized by progressive dysfunction without apparent relapse from the early clinical stages.
Although inflammation and demyelination in the CNS play central roles in MS pathogenesis, axonal degeneration was recently recognized to be crucial for the pathogenesis of MS, and is generally believed to be the main cause of irreversible neurological disability in the late and progressive phases of MS. 1, 2 Recent pathological and MRI studies have also shown that axonal degeneration is detectable even in the early clinical stages; accordingly, it is a hallmark of RRMS. 3, [28] [29] [30] MAI and their receptor, NgR1, have recently attracted attention as key molecules in MS-associated axonal degeneration. [31] [32] [33] Although signaling downstream of NgR1 is not fully understood, phosphorylation of collapsin response mediator protein-2 is an important substantial downstream factor in this pathway that is responsible for axonal degeneration in MS. 7 Collapsin response mediator protein-2 is a tubulin-associated protein involved in regulation of axonal growth, and its phosphorylation is related to neurodegeneration in Alzheimer's disease. [34] [35] [36] In addition, expression of Nogo, the most studied MAI, is prominently upregulated at active lesions with demyelination, as well as in the CSF of MS patients, suggesting that amplification of Nogo-NgR1 signaling aggravates MS pathogenesis. 6, 37 Together, these studies show that inhibition of binding between NgR1 and its ligands might prevent axonal degeneration in MS by attenuating NgR1-mediated signaling.
Potential application of LOTUS as a biomarker of MS
Elucidation of LOTUS function as an NgR1 antagonist prompted us to investigate its role in the pathogenesis of MS. In particular, we focused on the correlation between LOTUS and disease activity, because the degree of axonal degeneration is responsible for progression of functional disability. [3] [4] [5] In addition to our previous findings regarding LOTUS function in mice, proteomic studies also suggested that LOTUS is present in human CSF. 38 Using a biochemical approach, we successfully detected LOTUS in human CSF, and clarified the relationship between LOTUS levels in the CSF and clinical course or disease activity in MS. 39 In our analysis of CSF LOTUS levels, we initially divided the MS patients into RRMS and SPMS groups; those in the former group were classified into the relapse and remission groups according to findings of gadolinium-enhanced MRI lesions, medical history and clinical findings. LOTUS concentration was measured by quantitative immunoblotting.
The LOTUS concentration was lower in the relapse group of RRMS than in healthy controls (HC), but similar between the remission group and HC. In addition, follow-up data showed that a reduction of the LOTUS level in the relapse phase in RRMS patients recovered to the HC level during remission phase. On the contrary, in patients in the SPMS group with progressive clinical disability, the LOTUS concentration remained low and did not recover. In short, variations in the CSF LOTUS level corresponded to disease activity in both the early and progressive phases of MS (Fig. 2) . These data strongly corroborate the hypothesis that a decrease in LOTUS activates NgR1 signaling by attenuating antagonism NgR1 function, thereby triggering the pathological cascade leading to axonal degeneration. In RRMS, the LOTUS level in the relapse phase underwent a transient reduction, with minimum axonal damage, and recovered to the HC level in the remission phase concomitant with clinical improvement. In contrast, in the SPMS group, the LOTUS concentration remained low without recovery, potentially resulting in continuous progressive axonal degeneration, a characteristic pathological feature of SPMS.
Fast diagnosis and treatment are critical for functional recovery from MS attack, but the availability and sensitivity of conventional biomarkers are still insufficient for rapid diagnosis. Although gadolinium-enhanced MRI is used for detecting acute relapse lesions, its detection rate is approximately 50%, and its availability is generally limited to hospitals. 40 Conventional CSF biomarkers, such as oligoclonal immunoglobulin G bands and the immunoglobulin G index are also used as diagnostic tools for acute relapses in MS, [41] [42] [43] but the sensitivity of these biomarkers is just 30-60% in Asian populations, including Japanese patients. 44, 45 Our data strongly suggest that LOTUS represents a promising biomarker for evaluating disease activity and prognosis in both RRMS and SPMS patients.
Although it remains uncertain how LOTUS expression is regulated, a previous study by our group provided a clue regarding this mechanism. 46 Using lipopolysaccharide-injected mice as a disease model of neuroinflammation, we investigated the association between LOTUS and neuroinflammation. The results showed that the mRNA and protein levels of LOTUS in the CNS were inversely correlated with the extent of neuroinflammation, suggesting that stimuli by neuroinflammation downregulate LOTUS mRNA expression. Therefore, fluctuation in the CSF LOTUS level could be a biomarker of the extent of CNS neuroinflammation, and could therefore be useful for accurate diagnosis, appropriate therapy and comprehension of pathogenesis of MS.
LOTUS as a new therapeutic approach for MS
Beyond its potential application as a biomarker, LOTUS could be used as a therapeutic agent to promote axonal regeneration by its antagonistic effect on NgR1. Recently, a variety of disease-modifying therapies have been applied to MS treatment; primarily immunomodulators and immunosuppressants aimed at decreasing the rates of relapse and inflamed lesions. 47 However, because few therapies can promote the repair of axonal damage, these drugs do not enable patients to recover from neurological dysfunctions. To achieve that goal, it will be necessary to develop therapeutics that can inhibit axonal degeneration and promote axonal regeneration. Notably in this regard, recent studies showed that LOTUS strongly inhibits axonal degeneration and promotes axonal regeneration, resulting in functional recovery in CNS-injured animals, suggesting that it is a plausible therapeutic candidate for axonal regeneration in MS. [48] [49] [50] Consistent with this, our recent preliminary results suggest that LOTUS can contribute to axonal regeneration and functional recovery in animal models of MS (unpubl. data).
Conclusion
LOTUS, an endogenous antagonist of NgR1, represents a promising biomarker to evaluate disease activity as a result of CNS neuroinflammation in MS. In addition, LOTUS is an attractive therapeutic target for inhibition of axonal degeneration and promotion of axonal regeneration leading to functional recovery. Because the precise mechanisms of LOTUS regulation remain largely unknown, further studies are essential in order to elucidate the complex pathogenesis of MS.
